E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research

Online Publishing Date:
20 / 01 / 2023

 


Safety profile of CoviShield (ChAdOx1nCoV-19) vaccine among healthcare workers in a tertiary care hospital

Sruthi S, Melcy Mary Philip, Sai Nathan R, Seema P Mohamed Ali.


Abstract
Background: Coronavirus 2019 was declared as a pandemic by the World Health Organization in March 2020. Bereft of specific treatment for the disease, vaccinations and COVID appropriate behavior have come to be the main approaches to combat the pandemic. A number of vaccines have been approved after clearing clinical trials. Hence, it is essential to evaluate the safety profile of each vaccine for ensuring optimum health of the general population. This study was conducted to evaluate the adverse events following CoviShield vaccination in a tertiary care center.

Aims and Objectives: The aim of the study was to describe the pattern of adverse effects, treatment given, and comorbidities seen in healthcare workers (HCW) who reported to the adverse drug reaction (ADR) monitoring center in the department of pharmacology Government T.D. Medical College, Alappuzha, following CoviShield vaccination from January 2021 to October 2021.

Materials and Methods: A retrospective and descriptive study was carried out at Department of Pharmacology, GTDMCA involving all HCW who reported side effects following CoviShield vaccination in the ADR monitoring centre (AMC) in the Department of Pharmacology, GTDMCA from January 2021 to Oct 2021.

Results: Out of 620 HCWs who reported adverse event following vaccination, majority (45%) were from the age group 21–30 years. About 83% of HCWs who reported adverse effect were women. Majority of the respondents (96%) experienced the adverse effects within 24 h. About 88% of respondents experienced these adverse effects after the initial dose alone. Commonly encountered adverse effects were fever (57%), headache (43%), myalgia (38%) etc. Hypertension (7%) was the most common comorbidity seen. Majority of the beneficiaries (70%) took paracetamol for the treatment of the adverse effect.

Conclusion: Majority of the vaccinated HCWs experienced minor and self-limiting adverse event following immunization (AEFI) with Chimpanzee Adenovirus Oxford novel CoronaVirus-19. No serious AEFI were reported to the AMC. Despite the record speed at which the vaccine has been developed, it has shown to have a good safety profile considering the millions of doses that have been administered.

Key words: Coronavirus; CoviShield; Adverse Event; Healthcare Workers; Comorbidities; Drug Allergy


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Sruthi S
Articles by Melcy Mary Philip
Articles by Sai Nathan R
Articles by Seema P Mohamed Ali
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

S S, Philip MM, R SN, Ali SPM. Safety profile of CoviShield (ChAdOx1nCoV-19) vaccine among healthcare workers in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2023; 13(2): 425-429. doi:10.5455/njppp.2023.13.11556202211012023


Web Style

S S, Philip MM, R SN, Ali SPM. Safety profile of CoviShield (ChAdOx1nCoV-19) vaccine among healthcare workers in a tertiary care hospital. https://www.njppp.com/?mno=131064 [Access: March 14, 2024]. doi:10.5455/njppp.2023.13.11556202211012023


AMA (American Medical Association) Style

S S, Philip MM, R SN, Ali SPM. Safety profile of CoviShield (ChAdOx1nCoV-19) vaccine among healthcare workers in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2023; 13(2): 425-429. doi:10.5455/njppp.2023.13.11556202211012023



Vancouver/ICMJE Style

S S, Philip MM, R SN, Ali SPM. Safety profile of CoviShield (ChAdOx1nCoV-19) vaccine among healthcare workers in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. (2023), [cited March 14, 2024]; 13(2): 425-429. doi:10.5455/njppp.2023.13.11556202211012023



Harvard Style

S, S., Philip, . M. M., R, . S. N. & Ali, . S. P. M. (2023) Safety profile of CoviShield (ChAdOx1nCoV-19) vaccine among healthcare workers in a tertiary care hospital. Natl J Physiol Pharm Pharmacol, 13 (2), 425-429. doi:10.5455/njppp.2023.13.11556202211012023



Turabian Style

S, Sruthi, Melcy Mary Philip, Sai Nathan R, and Seema P Mohamed Ali. 2023. Safety profile of CoviShield (ChAdOx1nCoV-19) vaccine among healthcare workers in a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2), 425-429. doi:10.5455/njppp.2023.13.11556202211012023



Chicago Style

S, Sruthi, Melcy Mary Philip, Sai Nathan R, and Seema P Mohamed Ali. "Safety profile of CoviShield (ChAdOx1nCoV-19) vaccine among healthcare workers in a tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 425-429. doi:10.5455/njppp.2023.13.11556202211012023



MLA (The Modern Language Association) Style

S, Sruthi, Melcy Mary Philip, Sai Nathan R, and Seema P Mohamed Ali. "Safety profile of CoviShield (ChAdOx1nCoV-19) vaccine among healthcare workers in a tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 13.2 (2023), 425-429. Print. doi:10.5455/njppp.2023.13.11556202211012023



APA (American Psychological Association) Style

S, S., Philip, . M. M., R, . S. N. & Ali, . S. P. M. (2023) Safety profile of CoviShield (ChAdOx1nCoV-19) vaccine among healthcare workers in a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2), 425-429. doi:10.5455/njppp.2023.13.11556202211012023